Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000046190 | SCV000245966 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
Counsyl | RCV000046190 | SCV000486413 | pathogenic | Cystic fibrosis | 2016-05-24 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000046190 | SCV000886221 | pathogenic | Cystic fibrosis | 2018-11-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000046190 | SCV002684069 | pathogenic | Cystic fibrosis | 2018-07-26 | criteria provided, single submitter | clinical testing | The c.-9_14del23 pathogenic mutation, located in the 5' untranslated region and coding exon 1 of the CFTR gene, results from a deletion of 23 nucleotides at positions -9 to 14. This alters the methionine residue at the initiation codon (ATG). This mutation was detected in one individual with cystic fibrosis; however, complete genotype and phenotype information were not provided (Alonso MJ et al. Ann. Hum. Genet., 2007 Mar;71:194-201). In addition to the clinical data presented in the literature, since sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame, this alteration is interpreted as a disease-causing mutation. |
Natera, |
RCV000046190 | SCV001464062 | pathogenic | Cystic fibrosis | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004724786 | SCV005337447 | pathogenic | CFTR-related disorder | 2024-09-09 | no assertion criteria provided | clinical testing | The CFTR c.-9_14del23 variant is predicted to disrupt the translation initiation site (Start loss). This variant has been reported in at least eight alleles in cystic fibrosis screening studies and has been identified in a cohort of patients with Cystic Fibrosis of Spanish ancestry (Beauchamp et al. 2019. PubMed ID: 31036917; Raraigh et al. 2021. PubMed ID: 34782259; Alonso et al. 2007. PubMed ID: 17331079). This variant is also referred to in the literature as c.124del23bp, using legacy nomenclature. This variant has not been reported in a large population database, indicating it is rare. In ClinVar, this variant is classified as pathogenic, including by the CF Expert Panel (https://www.ncbi.nlm.nih.gov/clinvar/variation/53158/). This variant is interpreted as pathogenic. |